These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 26890495)

  • 1. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
    Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
    Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
    Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
    Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
    J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
    Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
    Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis.
    Song J; Jiang F; Liu H; Ding K; Ren Y; Li L; Wang G; Shao Z; Fu R
    J Clin Lab Anal; 2020 Feb; 34(2):e23057. PubMed ID: 31663630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with multiple myeloma and renal failure on novel regimens.
    Soleymanian T; Soleimani A; Musavi A; Mojtahedi K; Hamid G
    Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):335-40. PubMed ID: 26997388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
    Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
    Kastritis E; Anagnostopoulos A; Roussou M; Gika D; Matsouka C; Barmparousi D; Grapsa I; Psimenou E; Bamias A; Dimopoulos MA
    Haematologica; 2007 Apr; 92(4):546-9. PubMed ID: 17488666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
    Tessenow H; Holzvogt M; Holzvogt B; Andrea M; Heyn S; Schliwa T; Schwarz M; Zehrfeld T; Becker C; Pfrepper C; Franke GN; Krahl R; Jentzsch M; Leiblein S; Schwind S; Bill M; Vucinic V; Lange T; Niederwieser D; Pönisch W
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2049-2058. PubMed ID: 28534173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
    Cohen C; Royer B; Javaugue V; Szalat R; El Karoui K; Caulier A; Knebelmann B; Jaccard A; Chevret S; Touchard G; Fermand JP; Arnulf B; Bridoux F
    Kidney Int; 2015 Nov; 88(5):1135-43. PubMed ID: 26176826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
    Pönisch W; Moll B; Bourgeois M; Andrea M; Schliwa T; Heyn S; Schmalfeld M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Egert M; Stiegler R; Krahl R; Remane Y; Bachmann A; Lindner T; Weidhase L; Petros S; Fricke S; Vucinic V; Al Ali H; Niederwieser D
    J Cancer Res Clin Oncol; 2013 Nov; 139(11):1937-46. PubMed ID: 24046251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years.
    Matsue K; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuchi M
    Ann Hematol; 2010 Mar; 89(3):291-7. PubMed ID: 19693498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
    Ho PJ; Spencer A; Mollee P; Bryant CE; Enjeti AK; Horvath N; Butcher BE; Trotman J; Gibbs S; Joshua DE
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):543-552.e1. PubMed ID: 38702217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
    Niesvizky R; Flinn IW; Rifkin R; Gabrail N; Charu V; Clowney B; Essell J; Gaffar Y; Warr T; Neuwirth R; Zhu Y; Elliott J; Esseltine DL; Niculescu L; Reeves J
    J Clin Oncol; 2015 Nov; 33(33):3921-9. PubMed ID: 26056177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
    Heyne N; Denecke B; Guthoff M; Oehrlein K; Kanz L; Häring HU; Weisel KC
    Ann Hematol; 2012 May; 91(5):729-735. PubMed ID: 22170517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.
    Decourt A; Gondouin B; Delaroziere JC; Brunet P; Sallée M; Burtey S; Dussol B; Ivanov V; Costello R; Couchoud C; Jourde-Chiche N
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):431-41. PubMed ID: 26728585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New insights in the treatment of myeloma with renal failure].
    Moumas E; Hanf W; Desport E; Abraham J; Delbès S; Debiais C; Lacotte-Thierry L; Touchard G; Jaccard A; Fermand JP; Bridoux F
    Nephrol Ther; 2011 Nov; 7(6):457-66. PubMed ID: 21515102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
    Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
    Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.